ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Oral Testosterone Product Phase 3 Study Completed
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 18292" data-attributes="member: 3"><p>LPCN 1021 is a twice-a-day, oral testosterone product candidate with three simple oral dosing options that we expect will overcome the major shortcomings of existing products.</p><p></p><p> <a href="http://globenewswire.com/Tracker?data=zB3YmJGzdJQ3GRI3eULbrE2S0d3m-XiL4Pg9oPeL2mdQb3RZaJcbce_38OVEzOkv71BodupTBQeBmALRemS-BQ%3D%3D" target="_blank">Lipocine Inc.</a> (Nasdaq:<a href="http://globenewswire.com/News/Listing?symbol=LPCN&exchange=2" target="_blank">LPCN</a>), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety assessment portion of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (<a href="http://clinicaltrials.gov/show/NCT02081300" target="_blank">http://clinicaltrials.gov/show/NCT02081300</a>) evaluating efficacy and safety of LPCN 1021, an Oral Testosterone product, in hypogonadal men with low testosterone ("Low T"). Lipocine previously announced positive top line efficacy from the SOAR clinical study in September 2014 and expects to announce top-line results from the 52 week safety assessment portion of the SOAR clinical study by mid-year as well as file the New Drug Application ("NDA") with the U.S. Food and Drug Administration in the second half of this year.</p><p><a href="http://www.fiercedrugdelivery.com/press-releases/lipocine-announces-completion-lpcn-1021-oral-testosterone-phase-3-clinical-0" target="_blank">http://www.fiercedrugdelivery.com/press-releases/lipocine-announces-completion-lpcn-1021-oral-testosterone-phase-3-clinical-0</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 18292, member: 3"] LPCN 1021 is a twice-a-day, oral testosterone product candidate with three simple oral dosing options that we expect will overcome the major shortcomings of existing products. [URL="http://globenewswire.com/Tracker?data=zB3YmJGzdJQ3GRI3eULbrE2S0d3m-XiL4Pg9oPeL2mdQb3RZaJcbce_38OVEzOkv71BodupTBQeBmALRemS-BQ%3D%3D"]Lipocine Inc.[/URL] (Nasdaq:[URL="http://globenewswire.com/News/Listing?symbol=LPCN&exchange=2"]LPCN[/URL]), a specialty pharmaceutical company, today announced the completion of the last patient visit in the safety assessment portion of its Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study ([url]http://clinicaltrials.gov/show/NCT02081300[/url]) evaluating efficacy and safety of LPCN 1021, an Oral Testosterone product, in hypogonadal men with low testosterone ("Low T"). Lipocine previously announced positive top line efficacy from the SOAR clinical study in September 2014 and expects to announce top-line results from the 52 week safety assessment portion of the SOAR clinical study by mid-year as well as file the New Drug Application ("NDA") with the U.S. Food and Drug Administration in the second half of this year. [url]http://www.fiercedrugdelivery.com/press-releases/lipocine-announces-completion-lpcn-1021-oral-testosterone-phase-3-clinical-0[/url] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Oral Testosterone Product Phase 3 Study Completed
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top